Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: A randomized, double-blind, placebo-controlled crossover study

Keyphrases

• Placebo-controlled 100%
• Schizophrenic Patients 100%
• Randomized Double-blind 100%
• Tardive Dyskinesia 100%
• Piracetam 100%
• Placebo 20%
• Placebo Groups 20%
• Primary Outcome Measure 10%
• Antipsychotics 10%
• Specific Mechanisms 10%
• Placebo-controlled Trial 10%
• DSM-IV 10%
• Symptom Score 10%
• Schizoaffective 10%
• Clinical Global Impression 10%
• Extrapyramidal Symptoms 10%
• Group by 10%
• Clinical Trial Registry 10%
• Mental Hospital 10%
• DSM-IV-TR 10%
• Washout Period 10%
• Rapid-onset Dystonia-parkinsonism 10%
• Potent Antioxidant 10%
• Metabolic Enhancer 10%
• Neuroprotectors 10%
• Oral Preparation 10%

Neuroscience

• Placebo 100%
• Crossover Study 100%
• Tardive Dyskinesia 100%
• Piracetam 100%
• Enhancer Region 10%
• Antipsychotic 10%
• Extrapyramidal Symptoms 10%
• Parkinsonism 10%
• Antioxidant 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Tardive Dyskinesia 100%
• Piracetam 100%
• Symptom 30%
• Clinical Trial 10%
• Antioxidant 10%
• Deterioration 10%
• Antipsychotic 10%
• Extrapyramidal Symptoms 10%
• DSM-IV 10%
• Parkinsonism 10%
• DSM-IV-TR 10%
• Neuroprotectors 10%